(Q37390749)

English

Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia

scientific article published on 06 December 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia (English)

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

0 references

0 references

author name string

Nagahide Takahashi

1

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Masayoshi Takahashi

2

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Takayuki Saito

3

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Misuzu Iizumi

4

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Yuki Saito

5

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Hiroko Shimizu

6

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Taka Matsumura

7

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

language of work or name

0 references

publication date

6 December 2013

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Neuropsychiatric Disease and Treatment

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

9

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

1889-1898

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

copyright license

Creative Commons Attribution-NonCommercial 3.0 Unported

1 December 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3862510

6 September 2017

A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3862510

6 September 2017

The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3862510

6 September 2017

Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3862510

6 September 2017

A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3862510

6 September 2017

5-HT2 antagonism and EPS benefits: is there a causal connection?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3862510

28 September 2017

A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3862510

26 June 2018

Commentary: Race and mental health--more questions than answers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3862510

26 June 2018

A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3862510

2 September 2018

A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3862510

2 September 2018

Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3862510

2 September 2018

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3862510

2 September 2018

Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3862510

2 September 2018

D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate

1 reference

https://pubmed.ncbi.nlm.nih.gov/24353421

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/24353421

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2147/NDT.S54051

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37390749&oldid=2129400411"